BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009;136:187-195. [PMID: 18992248 DOI: 10.1053/j.gastro.2008.09.067] [Cited by in Crossref: 296] [Cited by in F6Publishing: 287] [Article Influence: 21.1] [Reference Citation Analysis]
Number Citing Articles
1 Li Z, Wang H, Chen Y, Wang Y, Li H, Han H, Chen T, Jin Q, Ji J. pH- and NIR Light-Responsive Polymeric Prodrug Micelles for Hyperthermia-Assisted Site-Specific Chemotherapy to Reverse Drug Resistance in Cancer Treatment. Small 2016;12:2731-40. [DOI: 10.1002/smll.201600365] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 13.3] [Reference Citation Analysis]
2 Antoniou G, Kountourakis P, Papadimitriou K, Vassiliou V, Papamichael D. Adjuvant therapy for resectable pancreatic adenocarcinoma: Review of the current treatment approaches and future directions. Cancer Treatment Reviews 2014;40:78-85. [DOI: 10.1016/j.ctrv.2013.05.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
3 Jamieson NB, Chang DK, Grimmond SM, Biankin AV. Can we move towards personalised pancreatic cancer therapy? Expert Rev Gastroenterol Hepatol 2014;8:335-8. [PMID: 24702631 DOI: 10.1586/17474124.2014.893820] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
4 Hagmann W, Faissner R, Schnölzer M, Löhr M, Jesnowski R. Membrane drug transporters and chemoresistance in human pancreatic carcinoma. Cancers (Basel) 2010;3:106-25. [PMID: 24212609 DOI: 10.3390/cancers3010106] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
5 Du L, DeFoe M, Ruzinova MB, Olsen JR, Wang-Gillam A. Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am 2015;29:717-26. [PMID: 26226906 DOI: 10.1016/j.hoc.2015.04.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
6 Liu M, Zhang Y, Yang J, Cui X, Zhou Z, Zhan H, Ding K, Tian X, Yang Z, Fung KA, Edil BH, Postier RG, Bronze MS, Fernandez-Zapico ME, Stemmler MP, Brabletz T, Li YP, Houchen CW, Li M. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells. Gastroenterology 2020;158:679-692.e1. [PMID: 31711924 DOI: 10.1053/j.gastro.2019.10.038] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
7 Takaori K, Bassi C, Biankin A, Brunner TB, Cataldo I, Campbell F, Cunningham D, Falconi M, Frampton AE, Furuse J, Giovannini M, Jackson R, Nakamura A, Nealon W, Neoptolemos JP, Real FX, Scarpa A, Sclafani F, Windsor JA, Yamaguchi K, Wolfgang C, Johnson CD;  IAP/EPC study group on the clinical managements of pancreatic cancer. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Pancreatology. 2016;16:14-27. [PMID: 26699808 DOI: 10.1016/j.pan.2015.10.013] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 6.6] [Reference Citation Analysis]
8 Tesfaye AA, Kamgar M, Azmi A, Philip PA. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther. 2018;18:131-148. [PMID: 29254387 DOI: 10.1080/14737140.2018.1417844] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
9 Suzuki R, Takagi T, Hikichi T, Konno N, Sugimoto M, Watanabe KO, Nakamura J, Waragai Y, Kikuchi H, Takasumi M, Watanabe H, Ohira H. Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer. Oncol Lett 2016;11:3441-5. [PMID: 27123132 DOI: 10.3892/ol.2016.4381] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
10 Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, Caramella C, Maréchal R, Van Laethem JL, Ducreux M. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer. 2016;57:10-22. [PMID: 26851397 DOI: 10.1016/j.ejca.2015.12.026] [Cited by in Crossref: 85] [Cited by in F6Publishing: 86] [Article Influence: 14.2] [Reference Citation Analysis]
11 Wang K, Baldwin GS, Nikfarjam M, He H. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. World J Gastroenterol 2018; 24(33): 3709-3723 [PMID: 30197477 DOI: 10.3748/wjg.v24.i33.3709] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
12 Bergman AM, Adema AD, Balzarini J, Bruheim S, Fichtner I, Noordhuis P, Fodstad O, Myhren F, Sandvold ML, Hendriks HR, Peters GJ. Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest New Drugs 2011;29:456-66. [PMID: 20066470 DOI: 10.1007/s10637-009-9377-7] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 4.7] [Reference Citation Analysis]
13 Young JD, Yao SY, Baldwin JM, Cass CE, Baldwin SA. The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. Mol Aspects Med. 2013;34:529-547. [PMID: 23506887 DOI: 10.1016/j.mam.2012.05.007] [Cited by in Crossref: 198] [Cited by in F6Publishing: 170] [Article Influence: 22.0] [Reference Citation Analysis]
14 Manuyakorn A, Paulus R, Farrell J, Dawson NA, Tze S, Cheung-Lau G, Hines OJ, Reber H, Seligson DB, Horvath S, Kurdistani SK, Guha C, Dawson DW. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J Clin Oncol 2010;28:1358-65. [PMID: 20142597 DOI: 10.1200/JCO.2009.24.5639] [Cited by in Crossref: 150] [Cited by in F6Publishing: 82] [Article Influence: 12.5] [Reference Citation Analysis]
15 Tatarian T, Jiang W, Leiby BE, Grigoli A, Jimbo M, Dabbish N, Neoptolemos JP, Greenhalf W, Costello E, Ghaneh P, Halloran C, Palmer D, Buchler M, Yeo CJ, Winter JM, Brody JR. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial. Ann Surg. 2018;267:364-369. [PMID: 27893535 DOI: 10.1097/sla.0000000000002088] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
16 Spratlin JL, Mackey JR. Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions. Cancers (Basel) 2010;2:2044-54. [PMID: 24281217 DOI: 10.3390/cancers2042044] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
17 Poplin E, Wasan H, Rolfe L, Raponi M, Ikdahl T, Bondarenko I, Davidenko I, Bondar V, Garin A, Boeck S, Ormanns S, Heinemann V, Bassi C, Evans TJ, Andersson R, Hahn H, Picozzi V, Dicker A, Mann E, Voong C, Kaur P, Isaacson J, Allen A. Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity. JCO 2013;31:4453-61. [DOI: 10.1200/jco.2013.51.0826] [Cited by in Crossref: 113] [Cited by in F6Publishing: 59] [Article Influence: 12.6] [Reference Citation Analysis]
18 Peng H, Chen R, Brentnall TA, Eng JK, Picozzi VJ, Pan S. Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy. Clin Proteomics. 2019;16:31. [PMID: 31346328 DOI: 10.1186/s12014-019-9251-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
19 Massey AE, Sikander M, Chauhan N, Kumari S, Setua S, Shetty AB, Mandil H, Kashyap VK, Khan S, Jaggi M, Yallapu MM, Hafeez BB, Chauhan SC. Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. Nanomedicine 2019;20:102027. [PMID: 31170509 DOI: 10.1016/j.nano.2019.102027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
20 Okamura Y, Boku N, Ghaneh P, Greenhalf W, Yasukawa S, Narimatsu H, Fukutomi A, Konishi M, Morinaga S, Toyama H, Maeda A, Shimizu Y, Nakamori S, Sata N, Yamakita K, Takahashi A, Takayama W, Yamaguchi R, Tomikawa M, Yanagisawa A, Neoptolemos JP, Uesaka K. Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical outcomes of adjuvant chemotherapy for pancreatic cancer: A collaborative study from the JASPAC 01 trial. Cancer Rep (Hoboken) 2021;:e1507. [PMID: 34327872 DOI: 10.1002/cnr2.1507] [Reference Citation Analysis]
21 Paproski RJ, Young JD, Cass CE. Predicting gemcitabine transport and toxicity in human pancreatic cancer cell lines with the positron emission tomography tracer 3'-deoxy-3'-fluorothymidine. Biochem Pharmacol 2010;79:587-95. [PMID: 19788890 DOI: 10.1016/j.bcp.2009.09.025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
22 Graham JS, Jamieson NB, Rulach R, Grimmond SM, Chang DK, Biankin AV. Pancreatic cancer genomics: where can the science take us? Clin Genet 2015;88:213-9. [PMID: 25388820 DOI: 10.1111/cge.12536] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
23 Attia F, Fathy S, Anani M, Hassan A, Attia F, Ibrahim G, Elazab M. Human equilibrative nucleoside transporter-1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma. J Clin Lab Anal 2020;34:e23457. [PMID: 32671914 DOI: 10.1002/jcla.23457] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Zhao X, Ma Y, Dong X, Zhang Z, Tian X, Zhao X, Yang Y. Molecular characterization of circulating tumor cells in pancreatic ductal adenocarcinoma: potential diagnostic and prognostic significance in clinical practice. Hepatobiliary Surg Nutr 2021;10:796-810. [PMID: 35004946 DOI: 10.21037/hbsn-20-383] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Krell J, Frampton AE, Jiao LR, Stebbing J. Can pharmacogenomics guide effective anticancer therapy in pancreatic ductal adenocarcinoma? Pharmacogenomics 2012;13:977-9. [PMID: 22838942 DOI: 10.2217/pgs.12.73] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
26 Mollaei M, Hassan ZM, Khorshidi F, Langroudi L. Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells? Transl Oncol 2021;14:101056. [PMID: 33684837 DOI: 10.1016/j.tranon.2021.101056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Sarabi M, Mais L, Oussaid N, Desseigne F, Guibert P, De La Fouchardiere C. Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. Oncol Lett. 2017;13:4917-4924. [PMID: 28599496 DOI: 10.3892/ol.2017.6061] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
28 Jordheim LP, Dumontet C. Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer? Biomark Med. 2013;7:663-671. [PMID: 23905902 DOI: 10.2217/bmm.13.48] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
29 Orlandi A, Calegari MA, Martini M, Cocomazzi A, Bagalà C, Indellicati G, Zurlo V, Basso M, Cassano A, Larocca LM, Barone C. Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse. Clin Transl Oncol 2016;18:988-95. [PMID: 26742940 DOI: 10.1007/s12094-015-1471-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
30 Renouf D, Moore M. Evolution of systemic therapy for advanced pancreatic cancer. Expert Rev Anticancer Ther 2010;10:529-40. [PMID: 20397918 DOI: 10.1586/era.10.21] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
31 Adiseshaiah PP, Crist RM, Hook SS, McNeil SE. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol 2016;13:750-65. [PMID: 27531700 DOI: 10.1038/nrclinonc.2016.119] [Cited by in Crossref: 115] [Cited by in F6Publishing: 113] [Article Influence: 19.2] [Reference Citation Analysis]
32 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/so140-6736(10)62307-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Chang JS, Choi SH, Lee Y, Kim KH, Park JY, Song SY, Cho A, Yun M, Lee JD, Seong J. Clinical usefulness of 18F-fluorodeoxyglucose-positron emission tomography in patients with locally advanced pancreatic cancer planned to undergo concurrent chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2014;90:126-133. [PMID: 25015206 DOI: 10.1016/j.ijrobp.2014.05.030] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
34 Nagathihalli NS, Nagaraju G. RAD51 as a potential biomarker and therapeutic target for pancreatic cancer. Biochim Biophys Acta 2011;1816:209-18. [PMID: 21807066 DOI: 10.1016/j.bbcan.2011.07.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 30] [Article Influence: 1.2] [Reference Citation Analysis]
35 Krishan M, Gudelsky GA, Desai PB, Genter MB. Manipulation of olfactory tight junctions using papaverine to enhance intranasal delivery of gemcitabine to the brain. Drug Deliv 2014;21:8-16. [PMID: 24116937 DOI: 10.3109/10717544.2013.840017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
36 Leisewitz AV, Zimmerman EI, Huang M, Jones SZ, Yang J, Graves LM. Regulation of ENT1 expression and ENT1-dependent nucleoside transport by c-Jun N-terminal kinase. Biochem Biophys Res Commun 2011;404:370-5. [PMID: 21145879 DOI: 10.1016/j.bbrc.2010.11.125] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
37 Kulsoom B, Shamsi TS, Afsar NA. Gene expression of hENT1, dCK, CDA, dCMPD and topoisomerase IIα as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin. Cancer Manag Res 2018;10:5573-89. [PMID: 30519105 DOI: 10.2147/CMAR.S181299] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Ohuchida K, Mizumoto K, Kayashima T, Fujita H, Moriyama T, Ohtsuka T, Ueda J, Nagai E, Hashizume M, Tanaka M. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann Surg Oncol 2011;18:2381-7. [PMID: 21347785 DOI: 10.1245/s10434-011-1602-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 4.7] [Reference Citation Analysis]
39 Cano-soldado P, Pastor-anglada M. Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition: TRANSPORTERS THAT TRANSLOCATE NUCLEOSIDES. Med Res Rev 2012;32:428-57. [DOI: 10.1002/med.20221] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
40 Crane CH, Iacobuzio-donahue CA. Keys to Personalized Care in Pancreatic Oncology. JCO 2012;30:4049-950. [DOI: 10.1200/jco.2012.45.1799] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
41 Puleo F, Maréchal R, Demetter P, Bali MA, Calomme A, Closset J, Bachet JB, Deviere J, Laethem JLV. New challenges in perioperative management of pancreatic cancer. World J Gastroenterol 2015; 21(8): 2281-2293 [PMID: 25741134 DOI: 10.3748/wjg.v21.i8.2281] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
42 Shimakata T, Kamoshida S, Kawamura J, Ogane N, Kameda Y, Yanagita E, Itoh T, Takeda R, Naka A, Sakamaki K, Hayashi Y, Kuwao S. Immunohistochemical expression profiles of solute carrier transporters in alpha-fetoprotein-producing gastric cancer. Histopathology 2016;69:812-21. [DOI: 10.1111/his.13004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
43 Bilici A. Prognostic factors related with survival in patients with pancreatic adenocarcinoma. World J Gastroenterol 2014; 20(31): 10802-10812 [PMID: 25152583 DOI: 10.3748/wjg.v20.i31.10802] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 76] [Article Influence: 9.8] [Reference Citation Analysis]
44 Faraoni EY, Ju C, Robson SC, Eltzschig HK, Bailey-lundberg JM. Purinergic and Adenosinergic Signaling in Pancreatobiliary Diseases. Front Physiol 2022;13:849258. [DOI: 10.3389/fphys.2022.849258] [Reference Citation Analysis]
45 Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. The Lancet 2004;363:1049-57. [DOI: 10.1016/s0140-6736(04)15841-8] [Cited by in Crossref: 1360] [Cited by in F6Publishing: 672] [Article Influence: 75.6] [Reference Citation Analysis]
46 Loosen SH, Neumann UP, Trautwein C, Roderburg C, Luedde T. Current and future biomarkers for pancreatic adenocarcinoma. Tumour Biol 2017;39:101042831769223. [DOI: 10.1177/1010428317692231] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
47 O'Reilly EM. Adjuvant therapy for pancreas adenocarcinoma. J Surg Oncol 2013;107:78-85. [PMID: 22886586 DOI: 10.1002/jso.23230] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
48 Ohuchida K, Ohtsuka T, Mizumoto K, Hashizume M, Tanaka M. Pancreatic Cancer: Clinical Significance of Biomarkers. Gastrointest Tumors 2013;1:33-40. [PMID: 26675163 DOI: 10.1159/000354996] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
49 Errasti-murugarren E, Pastor-anglada M. Drug transporter pharmacogenetics in nucleoside-based therapies. Pharmacogenomics 2010;11:809-41. [DOI: 10.2217/pgs.10.70] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
50 Kondo N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Sueda T. Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection. Ann Surg Oncol 2012;19 Suppl 3:S646-55. [PMID: 22086444 DOI: 10.1245/s10434-011-2140-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
51 Zhao X, Wang X, Sun W, Cheng K, Qin H, Han X, Lin Y, Wang Y, Lang J, Zhao R, Zheng X, Zhao Y, shi J, Hao J, Miao QR, Nie G, Ren H. Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment. Biomaterials 2018;158:44-55. [DOI: 10.1016/j.biomaterials.2017.12.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
52 Swords DS, Firpo MA, Scaife CL, Mulvihill SJ. Biomarkers in pancreatic adenocarcinoma: current perspectives. Onco Targets Ther 2016;9:7459-67. [PMID: 28003762 DOI: 10.2147/OTT.S100510] [Cited by in Crossref: 45] [Cited by in F6Publishing: 22] [Article Influence: 7.5] [Reference Citation Analysis]
53 Bjånes T, Kamčeva T, Eide T, Riedel B, Schjøtt J, Svardal A. Preanalytical Stability of Gemcitabine and its Metabolite 2′, 2′-Difluoro-2′-Deoxyuridine in Whole Blood—Assessed by Liquid Chromatography Tandem Mass Spectrometry. Journal of Pharmaceutical Sciences 2015;104:4427-32. [DOI: 10.1002/jps.24638] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
54 Wei CH, Gorgan TR, Elashoff DA, Hines OJ, Farrell JJ, Donahue TR. A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers. Pancreas. 2013;42:1303-1310. [PMID: 24152955 DOI: 10.1097/mpa.0b013e3182a23ae4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
55 Eto K, Kawakami H, Kuwatani M, Kudo T, Abe Y, Kawahata S, Takasawa A, Fukuoka M, Matsuno Y, Asaka M, Sakamoto N. Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer. Br J Cancer 2013;108:1488-94. [PMID: 23492684 DOI: 10.1038/bjc.2013.108] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
56 Tempero MA, Berlin J, Ducreux M, Haller D, Harper P, Khayat D, Schmoll HJ, Sobrero A, Van Cutsem E. Pancreatic cancer treatment and research: an international expert panel discussion. Ann Oncol. 2011;22:1500-1506. [PMID: 21199884 DOI: 10.1093/annonc/mdq545] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
57 Ansari D, Tingstedt B, Andersson R. Pancreatic cancer - cost for overtreatment with gemcitabine. Acta Oncol 2013;52:1146-51. [PMID: 23244671 DOI: 10.3109/0284186X.2012.744140] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
58 Van Laethem JL, Verslype C, Iovanna JL, Michl P, Conroy T, Louvet C, Hammel P, Mitry E, Ducreux M, Maraculla T. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Ann Oncol. 2012;23:570-576. [PMID: 21810728 DOI: 10.1093/annonc/mdr351] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 4.9] [Reference Citation Analysis]
59 Boeck S, Ormanns S, Haas M, Bächmann S, Laubender RP, Siveke JT, Jung A, Kirchner T, Heinemann V. Translational research in pancreatic cancer: KRAS and beyond.Pancreas. 2014;43:150-152. [PMID: 24326376 DOI: 10.1097/MPA.0b013e31829629f6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
60 Gusella M, Pasini F, Bolzonella C, Meneghetti S, Barile C, Bononi A, Toso S, Menon D, Crepaldi G, Modena Y, Stievano L, Padrini R. Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. Br J Clin Pharmacol 2011;71:437-44. [PMID: 21284703 DOI: 10.1111/j.1365-2125.2010.03838.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
61 Robins MJ, Peng Y, Damaraju VL, Mowles D, Barron G, Tackaberry T, Young JD, Cass CE. Improved Syntheses of 5′- S -(2-Aminoethyl)-6- N -(4-nitrobenzyl)-5′-thioadenosine (SAENTA), Analogues, and Fluorescent Probe Conjugates: Analysis of Cell-Surface Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels for Prediction of the Antitumor Efficacy of Gemcitabine. J Med Chem 2010;53:6040-53. [DOI: 10.1021/jm100432w] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
62 Puleo F, Demetter P, Eisendrath P, Maréchal R, Verset L, Toussaint E, Bachet J, Arvanitakis M, Mostafa I, Devière J, Van Laethem J. Feasibility of Immunohistochemistry on Endoscopic Ultrasound Fine-Needle Aspiration Samples for Evaluating Predictive Biomarkers in Pancreatic Cancer Management. Pancreas 2016;45:e50-2. [DOI: 10.1097/mpa.0000000000000672] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
63 Venugopal B, Awada A, Evans TR, Dueland S, Hendlisz A, Rasch W, Hernes K, Hagen S, Aamdal S. A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours. Cancer Chemother Pharmacol 2015;76:785-92. [PMID: 26289594 DOI: 10.1007/s00280-015-2846-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
64 Randazzo O, Papini F, Mantini G, Gregori A, Parrino B, Liu DSK, Cascioferro S, Carbone D, Peters GJ, Frampton AE, Garajova I, Giovannetti E. "Open Sesame?": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer. Cancers (Basel) 2020;12:E3206. [PMID: 33142664 DOI: 10.3390/cancers12113206] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
65 Ozaki T, Yu M, Yin D, Sun D, Zhu Y, Bu Y, Sang M. Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations. BMC Cancer 2018;18:309. [PMID: 29558908 DOI: 10.1186/s12885-018-4217-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
66 Elsaleh H, Farrell JJ, Crane CH. Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma? J Gastroenterol Hepatol 2009;24:708-10. [PMID: 19646012 DOI: 10.1111/j.1440-1746.2009.05838.x] [Reference Citation Analysis]
67 Khan S, Chauhan N, Yallapu MM, Ebeling MC, Balakrishna S, Ellis RT, Thompson PA, Balabathula P, Behrman SW, Zafar N, Singh MM, Halaweish FT, Jaggi M, Chauhan SC. Nanoparticle formulation of ormeloxifene for pancreatic cancer. Biomaterials 2015;53:731-43. [PMID: 25890768 DOI: 10.1016/j.biomaterials.2015.02.082] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
68 Li D, Pant S, Ryan DP, Laheru D, Bahary N, Dragovich T, Hosein PJ, Rolfe L, Saif MW, LaValle J, Yu KH, Lowery MA, Allen A, O'Reilly EM. A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression. Pancreatology 2014;14:398-402. [PMID: 25278310 DOI: 10.1016/j.pan.2014.07.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
69 Kalloger SE, Riazy M, Tessier-Cloutier B, Karasinska JM, Gao D, Peixoto RD, Samimi S, Chow C, Wong HL, Mackey JR, Renouf DJ, Schaeffer DF. A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine. J Pathol Clin Res 2017;3:179-90. [PMID: 28770102 DOI: 10.1002/cjp2.75] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
70 Avval ZM, Malekpour L, Raeisi F, Babapoor A, Mousavi SM, Hashemi SA, Salari M. Introduction of magnetic and supermagnetic nanoparticles in new approach of targeting drug delivery and cancer therapy application. Drug Metab Rev 2020;52:157-84. [PMID: 31834823 DOI: 10.1080/03602532.2019.1697282] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
71 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/s0140-6736(10)62307-0] [Cited by in Crossref: 1377] [Cited by in F6Publishing: 849] [Article Influence: 125.2] [Reference Citation Analysis]
72 Hsu MC, Pan MR, Chu PY, Tsai YL, Tsai CH, Shan YS, Chen LT, Hung WC. Protein Arginine Methyltransferase 3 Enhances Chemoresistance in Pancreatic Cancer by Methylating hnRNPA1 to Increase ABCG2 Expression. Cancers (Basel) 2018;11:E8. [PMID: 30577570 DOI: 10.3390/cancers11010008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
73 Henning JEK, Deutschbein T, Altieri B, Steinhauer S, Kircher S, Sbiera S, Wild V, Schlötelburg W, Kroiss M, Perotti P, Rosenwald A, Berruti A, Fassnacht M, Ronchi CL. Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. The Journal of Clinical Endocrinology & Metabolism 2017;102:4323-32. [DOI: 10.1210/jc.2017-01624] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
74 Amrutkar M, Gladhaug IP. Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers (Basel). 2017;9. [PMID: 29144412 DOI: 10.3390/cancers9110157] [Cited by in Crossref: 142] [Cited by in F6Publishing: 143] [Article Influence: 28.4] [Reference Citation Analysis]
75 Okamura Y, Yasukawa S, Narimatsu H, Boku N, Fukutomi A, Konishi M, Morinaga S, Toyama H, Kaneoka Y, Shimizu Y, Nakamori S, Sata N, Yamakita K, Takahashi A, Kainuma O, Hishinuma S, Yamaguchi R, Nagino M, Hirano S, Yanagisawa A, Mori K, Uesaka K. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy. Cancer Sci 2020;111:548-60. [PMID: 31778273 DOI: 10.1111/cas.14258] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
76 Ko AH, Tempero MA. Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology. 2009;136:43-45. [PMID: 19041649 DOI: 10.1053/j.gastro.2008.11.027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
77 Fontana A, Copetti M, Di Gangi IM, Mazza T, Tavano F, Gioffreda D, Mattivi F, Andriulli A, Vrhovsek U, Pazienza V. Development of a metabolites risk score for one-year mortality risk prediction in pancreatic adenocarcinoma patients. Oncotarget 2016;7:8968-78. [PMID: 26840268 DOI: 10.18632/oncotarget.7108] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
78 Smith RA, Tang J, Tudur-Smith C, Neoptolemos JP, Ghaneh P. Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer. 2011;104:1440-1451. [PMID: 21448172 DOI: 10.1038/bjc.2011.110] [Cited by in Crossref: 77] [Cited by in F6Publishing: 66] [Article Influence: 7.0] [Reference Citation Analysis]
79 El Hassouni B, Li Petri G, Liu DSK, Cascioferro S, Parrino B, Hassan W, Diana P, Ali A, Frampton AE, Giovannetti E. Pharmacogenetics of treatments for pancreatic cancer. Expert Opin Drug Metab Toxicol 2019;15:437-47. [PMID: 31100206 DOI: 10.1080/17425255.2019.1620731] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
80 Bird NT, Elmasry M, Jones R, Psarelli E, Dodd J, Malik H, Greenhalf W, Kitteringham N, Ghaneh P, Neoptolemos JP, Palmer D. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy. Br J Surg. 2017;104:328-336. [PMID: 28199010 DOI: 10.1002/bjs.10482] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
81 Yamada R, Mizuno S, Uchida K, Yoneda M, Kanayama K, Inoue H, Murata Y, Kuriyama N, Kishiwada M, Usui M, Ii N, Tsuboi J, Tano S, Hamada Y, Tanaka K, Horiki N, Ogura T, Shiraishi T, Takei Y, Katayama N, Isaji S. Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoing Gemcitabine-Based Chemoradiotherapy. Pancreas. 2016;45:761-771. [PMID: 26784908 DOI: 10.1097/mpa.0000000000000597] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
82 Fotopoulos G, Syrigos K, Saif MW. Genetic factors affecting patient responses to pancreatic cancer treatment. Ann Gastroenterol 2016;29:466-76. [PMID: 27708512 DOI: 10.20524/aog.2016.0056] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
83 Challapalli A, Barwick T, Pearson RA, Merchant S, Mauri F, Howell EC, Sumpter K, Maxwell RJ, Aboagye EO, Sharma R. 3’-Deoxy-3’-18F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer. Eur J Nucl Med Mol Imaging. 2015;42:831-840. [PMID: 25673055 DOI: 10.1007/s00259-015-3000-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
84 Joyce H, McCann A, Clynes M, Larkin A. Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism. Expert Opin Drug Metab Toxicol 2015;11:795-809. [PMID: 25836015 DOI: 10.1517/17425255.2015.1028356] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
85 Stuurman FE, Lolkema MP, Huitema AD, Soetekouw PM, Rosing H, Rolfe L, Kaur P, Beijnen JH, van Tinteren H, Voest EE, Schellens JH. A phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumors. J Clin Pharmacol 2013;53:878-83. [PMID: 23775853 DOI: 10.1002/jcph.108] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
86 dos Santos LV, de Andrade DP, Lima JP. FOLFIRINOX: a great leap forward, but for whom? J Clin Oncol 2012;30:114-5; author reply 114. [PMID: 22124105 DOI: 10.1200/JCO.2011.39.4056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
87 Thorn CF, Marsh S, Carrillo MW, McLeod HL, Klein TE, Altman RB. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics. 2011;21:237-242. [PMID: 20601926 DOI: 10.1097/fpc.0b013e32833c6107] [Cited by in Crossref: 19] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
88 Coppola S, Carnevale I, Danen EHJ, Peters GJ, Schmidt T, Assaraf YG, Giovannetti E. A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer. Drug Resist Updat 2017;31:43-51. [PMID: 28867243 DOI: 10.1016/j.drup.2017.07.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
89 Carter CJ, Mekkawy AH, Morris DL. Role of human nucleoside transporters in pancreatic cancer and chemoresistance. World J Gastroenterol 2021; 27(40): 6844-6860 [PMID: 34790010 DOI: 10.3748/wjg.v27.i40.6844] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
90 Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol 2014; 20(32): 11142-11159 [PMID: 25170201 DOI: 10.3748/wjg.v20.i32.11142] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 73] [Article Influence: 10.3] [Reference Citation Analysis]
91 Jin HB, Lu L, Xie L, Yang JF, Zhang XF, Ma SL. Concentration changes in gemcitabine and its metabolites after hyperthermia in pancreatic cancer cells assessed using RP-HPLC. Cell Mol Biol Lett 2019;24:30. [PMID: 31131010 DOI: 10.1186/s11658-019-0153-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
92 el Aziz LM. Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL. Med Oncol 2014;31:244. [PMID: 25294423 DOI: 10.1007/s12032-014-0244-9] [Reference Citation Analysis]
93 Rosendahl AH, Sun C, Wu D, Andersson R. Polysaccharide-K (PSK) increases p21(WAF/Cip1) and promotes apoptosis in pancreatic cancer cells. Pancreatology 2012;12:467-74. [PMID: 23217280 DOI: 10.1016/j.pan.2012.09.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
94 Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, Manabe T, Ohtsuka T, Tanaka M. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia. 2010;12:807-817. [PMID: 20927319 DOI: 10.1593/neo.10458] [Cited by in Crossref: 106] [Cited by in F6Publishing: 105] [Article Influence: 9.6] [Reference Citation Analysis]
95 Perrone G, Morini S, Santini D, Rabitti C, Vincenzi B, Alloni R, Antinori A, Magistrelli P, Lai R, Cass C, Mackey JR, Coppola R, Tonini G, Onetti Muda A. Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes. Eur J Histochem 2010;54:e38. [PMID: 20839414 DOI: 10.4081/ejh.2010.e38] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
96 Fisher SB, Patel SH, Bagci P, Kooby DA, El-Rayes BF, Staley CA, Adsay NV, Maithel SK. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment. Cancer. 2013;119:445-453. [PMID: 22569992 DOI: 10.1002/cncr.27619] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
97 Kell DB, Oliver SG. How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. Front Pharmacol 2014;5:231. [PMID: 25400580 DOI: 10.3389/fphar.2014.00231] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 11.6] [Reference Citation Analysis]
98 Huang X, Zheng J, Li J, Che X, Tan W, Tan W, Shao M, Cheng X, Du Z, Zhao Y, Wang C, Wu C, Lin D. Functional role of BTB and CNC Homology 1 gene in pancreatic cancer and its association with survival in patients treated with gemcitabine. Theranostics 2018;8:3366-79. [PMID: 29930735 DOI: 10.7150/thno.23978] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
99 Buxbaum JL, Eloubeidi MA. Recent advances in diagnostic and therapeutic endoscopic ultrasound. Expert Review of Gastroenterology & Hepatology 2014;6:525-7. [DOI: 10.1586/egh.12.44] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
100 Nahire R, Haldar MK, Paul S, Ambre AH, Meghnani V, Layek B, Katti KS, Gange KN, Singh J, Sarkar K, Mallik S. Multifunctional polymersomes for cytosolic delivery of gemcitabine and doxorubicin to cancer cells. Biomaterials 2014;35:6482-97. [PMID: 24797878 DOI: 10.1016/j.biomaterials.2014.04.026] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 8.1] [Reference Citation Analysis]
101 Bachet JB, Hammel P, Desramé J, Meurisse A, Chibaudel B, André T, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Meyer VG, Taieb J, Volet J, Monier A, Bonnetain F, Louvet C. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. Lancet Gastroenterol Hepatol 2017;2:337-46. [PMID: 28397697 DOI: 10.1016/S2468-1253(17)30046-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 4.6] [Reference Citation Analysis]
102 Chiu JW, Wong H, Leung R, Pang R, Cheung TT, Fan ST, Poon R, Yau T. Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. Oncologist 2014;19:937-50. [PMID: 25117068 DOI: 10.1634/theoncologist.2012-0131] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
103 Yamamoto M, Sanomachi T, Suzuki S, Uchida H, Yonezawa H, Higa N, Takajo T, Yamada Y, Sugai A, Togashi K, Seino S, Okada M, Sonoda Y, Hirano H, Yoshimoto K, Kitanaka C. Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma. Neuro Oncol 2021;23:945-54. [PMID: 33556172 DOI: 10.1093/neuonc/noab015] [Reference Citation Analysis]
104 Yegya-Raman N, Shah MM, Grandhi MS, Poplin E, August DA, Kennedy TJ, Malhotra U, Spencer KR, Carpizo DR, Jabbour SK. Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma. Ann Pancreat Cancer 2018;1:20. [PMID: 30687847 DOI: 10.21037/apc.2018.07.05] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
105 Nordh S, Ansari D, Andersson R. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review. World J Gastroenterol 2014; 20(26): 8482-8490 [PMID: 25024604 DOI: 10.3748/wjg.v20.i26.8482] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 53] [Article Influence: 7.0] [Reference Citation Analysis]
106 Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Bhosale PR, Tamm EP, Crane CH. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest. 2014;124:1525-1536. [PMID: 24614108 DOI: 10.1172/jci73455] [Cited by in Crossref: 121] [Cited by in F6Publishing: 89] [Article Influence: 15.1] [Reference Citation Analysis]
107 Nishio R, Tsuchiya H, Yasui T, Matsuura S, Kanki K, Kurimasa A, Hisatome I, Shiota G. Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd). Cancer Sci 2011;102:622-9. [PMID: 21205085 DOI: 10.1111/j.1349-7006.2010.01837.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
108 Wright NJ, Lee SY. Structures of human ENT1 in complex with adenosine reuptake inhibitors. Nat Struct Mol Biol 2019;26:599-606. [PMID: 31235912 DOI: 10.1038/s41594-019-0245-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
109 Ciccolini J, Serdjebi C, Peters GJ, Giovannetti E. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol. 2016;78:1-12. [PMID: 27007129 DOI: 10.1007/s00280-016-3003-0] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 12.5] [Reference Citation Analysis]
110 Hillgren KM, Keppler D, Zur AA, Giacomini KM, Stieger B, Cass CE, Zhang L; International Transporter Consortium. Emerging transporters of clinical importance: an update from the International Transporter Consortium. Clin Pharmacol Ther 2013;94:52-63. [PMID: 23588305 DOI: 10.1038/clpt.2013.74] [Cited by in Crossref: 232] [Cited by in F6Publishing: 210] [Article Influence: 25.8] [Reference Citation Analysis]
111 Morinaga S, Nakamura Y, Watanabe T, Mikayama H, Tamagawa H, Yamamoto N, Shiozawa M, Akaike M, Ohkawa S, Kameda Y, Miyagi Y. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy. Ann Surg Oncol 2012;19 Suppl 3:S558-64. [PMID: 21913012 DOI: 10.1245/s10434-011-2054-z] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
112 Archibugi L, Testoni SGG, Redegalli M, Petrone MC, Reni M, Falconi M, Doglioni C, Capurso G, Arcidiacono PG. New era for pancreatic endoscopic ultrasound: From imaging to molecular pathology of pancreatic cancer. World J Gastrointest Oncol 2019; 11(11): 933-945 [PMID: 31798775 DOI: 10.4251/wjgo.v11.i11.933] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
113 Brocato T, Dogra P, Koay EJ, Day A, Chuang YL, Wang Z, Cristini V. Understanding Drug Resistance in Breast Cancer with Mathematical Oncology. Curr Breast Cancer Rep 2014;6:110-20. [PMID: 24891927 DOI: 10.1007/s12609-014-0143-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
114 Raffenne J, Nicolle R, Puleo F, Le Corre D, Boyez C, Marechal R, Emile JF, Demetter P, Bardier A, Laurent-Puig P, de Mestier L, Paradis V, Couvelard A, VanLathem JL, MacKey JR, Bachet JB, Svrcek M, Cros J. hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status. Cancers (Basel) 2019;11:E1808. [PMID: 31752123 DOI: 10.3390/cancers11111808] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
115 Benavides M, Abad A, Ales I, Carrato A, Díaz Rubio E, Gallego J, García-foncillas J, Grávalos C, Laquente B, Pericay C, Rivera F, Tabernero J, Aranda E. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. Clin Transl Oncol 2014;16:865-78. [DOI: 10.1007/s12094-014-1177-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
116 Grixti JM, O'Hagan S, Day PJ, Kell DB. Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine. Front Pharmacol 2017;8:155. [PMID: 28396636 DOI: 10.3389/fphar.2017.00155] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
117 Trouilloud I, Dubreuil O, Boussaha T, Lepère C, Landi B, Zaanan A, Bachet JB, Taieb J. Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine. Clin Res Hepatol Gastroenterol 2011;35:364-74. [PMID: 21435966 DOI: 10.1016/j.clinre.2011.02.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
118 Daman Z, Faghihi H, Montazeri H. Salinomycin nanoparticles interfere with tumor cell growth and the tumor microenvironment in an orthotopic model of pancreatic cancer. Drug Dev Ind Pharm 2018;44:1434-42. [PMID: 29619850 DOI: 10.1080/03639045.2018.1459674] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
119 Abrams MJ, Rakszawski K, Vasekar M, Passero F, Abbas A, Jia Y, Saif MW. Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology. Therap Adv Gastroenterol 2016;9:141-51. [PMID: 26929776 DOI: 10.1177/1756283X15622601] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
120 Mohelnikova-Duchonova B, Brynychova V, Hlavac V, Kocik M, Oliverius M, Hlavsa J, Honsova E, Mazanec J, Kala Z, Melichar B. The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer. Cancer Chemother Pharmacol. 2013;72:669-682. [PMID: 23934321 DOI: 10.1007/s00280-013-2246-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
121 Paproski RJ, Wuest M, Jans H, Graham K, Gati WP, Mcquarrie S, Mcewan A, Mercer J, Young JD, Cass CE. Biodistribution and Uptake of 3′-Deoxy-3′-Fluorothymidine in ENT1-Knockout Mice and in an ENT1-Knockdown Tumor Model. J Nucl Med 2010;51:1447-55. [DOI: 10.2967/jnumed.110.076356] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
122 O’Reilly EM. Evolving panorama of treatment for metastatic pancreas adenocarcinoma. J Clin Oncol. 2013;31:1621-1623. [PMID: 23547071 DOI: 10.1200/jco.2013.48.7660] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
123 Puleo F, Nicolle R, Blum Y, Cros J, Marisa L, Demetter P, Quertinmont E, Svrcek M, Elarouci N, Iovanna J, Franchimont D, Verset L, Galdon MG, Devière J, de Reyniès A, Laurent-puig P, Van Laethem J, Bachet J, Maréchal R. Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features. Gastroenterology 2018;155:1999-2013.e3. [DOI: 10.1053/j.gastro.2018.08.033] [Cited by in Crossref: 155] [Cited by in F6Publishing: 135] [Article Influence: 38.8] [Reference Citation Analysis]
124 Hwang DW, Shin E, Cho JY, Han HS, Yoon YS. Human equilibrative nucleoside transporter-1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression; do they have survival impact to pancreatic cancer? Ann Hepatobiliary Pancreat Surg 2020;24:127-36. [PMID: 32457256 DOI: 10.14701/ahbps.2020.24.2.127] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
125 Lamarca A, Asselin M, Manoharan P, Mcnamara MG, Trigonis I, Hubner R, Saleem A, Valle JW. 18F-FLT PET imaging of cellular proliferation in pancreatic cancer. Critical Reviews in Oncology/Hematology 2016;99:158-69. [DOI: 10.1016/j.critrevonc.2015.12.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
126 Vincenzi B, Stacchiotti S, Collini P, Pantano F, Rabitti C, Perrone G, Iuliani M, Baldi A, Badalamenti G, Sanfilippo R, Santini D, Muda AO, Gronchi A, Casali P, Dei Tos AP, Tonini G. Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. Br J Cancer 2017;117:340-6. [PMID: 28641307 DOI: 10.1038/bjc.2017.187] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
127 Maréchal R, Bachet J, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier–dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, André T, Dumontet C, Cass CE, Jordheim LP, Matera E, Closset J, Salmon I, Devière J, Emile J, Van Laethem J. Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma. Gastroenterology 2012;143:664-674.e6. [DOI: 10.1053/j.gastro.2012.06.006] [Cited by in Crossref: 163] [Cited by in F6Publishing: 163] [Article Influence: 16.3] [Reference Citation Analysis]
128 Kim R, Tan A, Lai KK, Jiang J, Wang Y, Rybicki LA, Liu X. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. Cancer 2011;117:3126-34. [PMID: 21264835 DOI: 10.1002/cncr.25883] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
129 Schwarz L, Vernerey D, Bachet JB, Tuech JJ, Portales F, Michel P, Cunha AS. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). BMC Cancer 2018;18:762. [PMID: 30041614 DOI: 10.1186/s12885-018-4663-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
130 Colbert LE, Fisher SB, Hardy CW, Hall WA, Saka B, Shelton JW, Petrova AV, Warren MD, Pantazides BG, Gandhi K. Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma. Cancer. 2013;119:3148-3155. [PMID: 23720157 DOI: 10.1002/cncr.28144] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 6.8] [Reference Citation Analysis]
131 Dhar D, Raina K, Kumar D, Wempe MF, Bagby SM, Pitts TM, Orlicky DJ, Agarwal C, Messersmith WA, Agarwal R. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors. Mol Carcinog 2020;59:1227-40. [PMID: 32816368 DOI: 10.1002/mc.23251] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
132 Ansari D, Torén W, Zhou Q, Hu D, Andersson R. Proteomic and genomic profiling of pancreatic cancer. Cell Biol Toxicol 2019;35:333-43. [PMID: 30771135 DOI: 10.1007/s10565-019-09465-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 9.7] [Reference Citation Analysis]
133 Elebro J, Ben Dror L, Heby M, Nodin B, Jirström K, Eberhard J. Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer. Acta Oncol 2016;55:286-96. [PMID: 26362587 DOI: 10.3109/0284186X.2015.1075663] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
134 Soo RA, Yong WP, Innocenti F. Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets 2012;13:811-28. [PMID: 22458528 DOI: 10.2174/138945012800564068] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
135 Zhu Y, Qi M, Lao L, Wang W, Hua L, Bai G. Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis. Genet Test Mol Biomarkers. 2014;18:306-312. [PMID: 24625353 DOI: 10.1089/gtmb.2013.0419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
136 Aarnink A, Richard C, Truntzer C, Vincent J, Bengrine L, Vienot A, Borg C, Ghiringhelli F. Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma. Oncotarget 2018;9:25617-29. [PMID: 29876012 DOI: 10.18632/oncotarget.25424] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
137 Kruger S, Haas M, Ormanns S, Bächmann S, Siveke JT, Kirchner T, Heinemann V, Boeck S. Translational research in pancreatic ductal adenocarcinoma: Current evidence and future concepts. World J Gastroenterol 2014; 20(31): 10769-10777 [PMID: 25152580 DOI: 10.3748/wjg.v20.i31.10769] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
138 Kim J, Kim H, Lee JC, Kim JW, Paik WH, Lee SH, Hwang JH, Ryu JK, Kim YT. Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer. PLoS One 2018;13:e0209104. [PMID: 30557411 DOI: 10.1371/journal.pone.0209104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
139 Conroy T, Mitry E. [Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results]. Bull Cancer 2011;98:1439-46. [PMID: 22133915 DOI: 10.1684/bdc.2011.1494] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
140 Giovannetti E, Toffalorio F, De Pas T, Peters GJ. Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape? Pharmacogenomics 2012;13:1073-86. [PMID: 22838953 DOI: 10.2217/pgs.12.91] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
141 Damaraju VL, Sawyer MB, Mackey JR, Young JD, Cass CE. Human nucleoside transporters: biomarkers for response to nucleoside drugs. Nucleosides Nucleotides Nucleic Acids 2009;28:450-63. [PMID: 20183595 DOI: 10.1080/15257770903044499] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
142 Danielsson K, Ansari D, Andersson R. Personalizing pancreatic cancer medicine: what are the challenges? Personalized Medicine 2013;10:45-59. [DOI: 10.2217/pme.12.111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
143 Aughton K, Elander NO, Evans A, Jackson R, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, Carter R, Cunningham D, Tebbutt NC, Goldstein D, Shannon J, Glimelius B, Hackert T, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Palmer DH, Büchler MW, Ghaneh P, Neoptolemos JP, Greenhalf W. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Cancers (Basel) 2021;13:5758. [PMID: 34830914 DOI: 10.3390/cancers13225758] [Reference Citation Analysis]
144 McAllister F, Pineda DM, Jimbo M, Lal S, Burkhart RA, Moughan J, Winter KA, Abdelmohsen K, Gorospe M, Acosta Ade J, Lankapalli RH, Winter JM, Yeo CJ, Witkiewicz AK, Iacobuzio-Donahue CA, Laheru D, Brody JR. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial. Cancer Biol Ther 2014;15:688-98. [PMID: 24618665 DOI: 10.4161/cbt.28413] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
145 Bjånes T, Kotopoulis S, Murvold ET, Kamčeva T, Gjertsen BT, Gilja OH, Schjøtt J, Riedel B, McCormack E. Ultrasound- and Microbubble-Assisted Gemcitabine Delivery to Pancreatic Cancer Cells. Pharmaceutics 2020;12:E141. [PMID: 32046005 DOI: 10.3390/pharmaceutics12020141] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
146 Moysan E, Bastiat G, Benoit JP. Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications. Mol Pharm. 2013;10:430-444. [PMID: 22978251 DOI: 10.1021/mp300370t] [Cited by in Crossref: 123] [Cited by in F6Publishing: 116] [Article Influence: 12.3] [Reference Citation Analysis]
147 Hasan S, Jacob R, Manne U, Paluri R. Advances in pancreatic cancer biomarkers. Oncol Rev 2019;13:410. [PMID: 31044028 DOI: 10.4081/oncol.2019.410] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 13.0] [Reference Citation Analysis]
148 Greenhalf W, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, Mackey JR, Costello E. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst. 2014;106:djt347. [PMID: 24301456 DOI: 10.1093/jnci/djt347] [Cited by in Crossref: 166] [Cited by in F6Publishing: 152] [Article Influence: 18.4] [Reference Citation Analysis]
149 Ormanns S, Heinemann V, Raponi M, Isaacson J, Laubender RP, Haas M, Kruger S, Kleespies A, Mann E, Bartosiewicz M, Kirchner T, Boeck S. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: Translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. European Journal of Cancer 2014;50:1891-9. [DOI: 10.1016/j.ejca.2014.04.023] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
150 Ying JE, Zhu LM, Liu BX. Developments in metastatic pancreatic cancer: Is gemcitabine still the standard? World J Gastroenterol 2012; 18(8): 736-745 [PMID: 22371633 DOI: 10.3748/wjg.v18.i8.736] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
151 Okano K, Suzuki Y. Strategies for early detection of resectable pancreatic cancer. World J Gastroenterol 2014; 20(32): 11230-11240 [PMID: 25170207 DOI: 10.3748/wjg.v20.i32.11230] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
152 Sjoquist KM, Chin VT, Chantrill LA, O’Connor C, Hemmings C, Chang DK, Chou A, Pajic M, Johns AL, Nagrial AM, Biankin AV, Yip D. Personalising pancreas cancer treatment: When tissue is the issue. World J Gastroenterol 2014; 20(24): 7849-7863 [PMID: 24976722 DOI: 10.3748/wjg.v20.i24.7849] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
153 Kang CM, Hwang HK, Lee WJ. Pancreas club international joint symposium on pancreatic cancer 2012, Kyoto: down staging chemo±radiotherapy for borderline resectable pancreatic cancer. Korean J Hepatobiliary Pancreat Surg 2013;17:8-13. [PMID: 26155207 DOI: 10.14701/kjhbps.2013.17.1.8] [Reference Citation Analysis]
154 Neuzillet C, Sauvanet A, Hammel P. Prognostic factors for resectable pancreatic adenocarcinoma. Journal of Visceral Surgery 2011;148:e232-43. [DOI: 10.1016/j.jviscsurg.2011.07.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
155 Wu Z, Xu J, Liang C, Meng Q, Hua J, Wang W, Zhang B, Liu J, Yu X, Shi S. Emerging roles of the solute carrier family in pancreatic cancer. Clin Transl Med 2021;11:e356. [PMID: 33783998 DOI: 10.1002/ctm2.356] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
156 Boswell-Casteel RC, Hays FA. Equilibrative nucleoside transporters-A review. Nucleosides Nucleotides Nucleic Acids 2017;36:7-30. [PMID: 27759477 DOI: 10.1080/15257770.2016.1210805] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 12.5] [Reference Citation Analysis]
157 Mas L, Schwarz L, Bachet JB. Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives. Curr Opin Oncol 2020;32:356-63. [PMID: 32541325 DOI: 10.1097/CCO.0000000000000639] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
158 Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P, Peeters M, Polus M, Praet M, Mauer M, Collette L, Budach V, Lutz M, Van Cutsem E, Haustermans K. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol. 2010;28:4450-4456. [PMID: 20837948 DOI: 10.1200/jco.2010.30.3446] [Cited by in Crossref: 184] [Cited by in F6Publishing: 73] [Article Influence: 15.3] [Reference Citation Analysis]
159 Tavano F, Fontana A, Pellegrini F, Burbaci FP, Rappa F, Cappello F, Copetti M, Maiello E, Lombardi L, Graziano P, Vinciguerra M, di Mola FF, di Sebastiano P, Andriulli A, Pazienza V. Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients. J Transl Med 2014;12:248. [PMID: 25199538 DOI: 10.1186/s12967-014-0248-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
160 Aoyama T, Kazama K, Miyagi Y, Murakawa M, Yamaoku K, Atsumi Y, Shiozawa M, Ueno M, Morimoto M, Oshima T, Yukawa N, Yoshikawa T, Rino Y, Masuda M, Morinaga S. Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant chemotherapy. Oncol Lett 2017;14:599-606. [PMID: 28693211 DOI: 10.3892/ol.2017.6220] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
161 Lin H, Hu C, Zheng S, Zhang X, Chen R, Zhou Q. A novel gene signature for prognosis prediction and chemotherapy response in patients with pancreatic cancer. Aging (Albany NY) 2021;13:12493-513. [PMID: 33901011 DOI: 10.18632/aging.202922] [Reference Citation Analysis]
162 Parsian M, Mutlu P, Yalcin S, Gunduz U. Characterization of Gemcitabine Loaded Polyhydroxybutyrate Coated Magnetic Nanoparticles for Targeted Drug Delivery. Anticancer Agents Med Chem 2020;20:1233-40. [PMID: 32156242 DOI: 10.2174/1871520620666200310091026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
163 Veras MA, Tenn NA, Kuljanin M, Lajoie GA, Hammond JR, Dixon SJ, Séguin CA. Loss of ENT1 increases cell proliferation in the annulus fibrosus of the intervertebral disc. J Cell Physiol 2019;234:13705-19. [PMID: 31010267 DOI: 10.1002/jcp.28051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
164 Sultana A, Cox T, Ghaneh P, Neoptolemos JP. Adjuvant therapy for pancreatic cancer. Recent Results Cancer Res. 2012;196:65-88. [PMID: 23129367 DOI: 10.1007/978-3-642-31629-6_5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
165 Akahoshi K, Ban D, Kuboki R, Oba A, Ono H, Mitsunori Y, Kudo A, Tanaka S, Tanabe M. Orotate phosphoribosyltransferase as a predictor of benefit from S‐1 adjuvant chemotherapy for cholangiocarcinoma patients. Journal of Gastroenterology and Hepatology 2018;34:1108-15. [DOI: 10.1111/jgh.14477] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
166 Moysan E, González-fernández Y, Lautram N, Béjaud J, Bastiat G, Benoit J. An innovative hydrogel of gemcitabine-loaded lipid nanocapsules: when the drug is a key player of the nanomedicine structure. Soft Matter 2014;10:1767. [DOI: 10.1039/c3sm52781f] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
167 Espinoza JA, García P, Bizama C, Leal JL, Riquelme I, Weber H, Macanas P, Aguayo G, Viñuela E, Roa JC, Nervi B. Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients. Histopathology 2016;68:722-8. [PMID: 26266900 DOI: 10.1111/his.12805] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
168 Wright NJ, Lee SY. Toward a Molecular Basis of Cellular Nucleoside Transport in Humans. Chem Rev 2021;121:5336-58. [PMID: 33232132 DOI: 10.1021/acs.chemrev.0c00644] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
169 Oba A, Ban D, Kirimura S, Akahoshi K, Mitsunori Y, Matsumura S, Ochiai T, Kudo A, Tanaka S, Minoru T. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma: Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci 2016;23:480-8. [DOI: 10.1002/jhbp.366] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
170 Bridges E, Harris AL. Vascular-promoting therapy reduced tumor growth and progression by improving chemotherapy efficacy. Cancer Cell 2015;27:7-9. [PMID: 25584889 DOI: 10.1016/j.ccell.2014.12.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
171 Ducreux M, Seufferlein T, Van Laethem JL, Laurent-Puig P, Smolenschi C, Malka D, Boige V, Hollebecque A, Conroy T. Systemic treatment of pancreatic cancer revisited. Semin Oncol 2019;46:28-38. [PMID: 30638624 DOI: 10.1053/j.seminoncol.2018.12.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
172 Huang TC, Kar S, Javle M. Personalized therapy for pancreatic cancer: Myth or reality in 2010? J Gastrointest Oncol 2010;1:24-33. [PMID: 22811802 DOI: 10.3978/j.issn.2078-6891.2010.009] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
173 Li D, O'Reilly EM. Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma. Semin Oncol 2015;42:134-43. [PMID: 25726058 DOI: 10.1053/j.seminoncol.2014.12.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
174 Murata Y, Hamada T, Kishiwada M, Ohsawa I, Mizuno S, Usui M, Sakurai H, Tabata M, Ii N, Inoue H, Shiraishi T, Isaji S. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy. J Hepatobiliary Pancreat Sci 2012;19:413-25. [PMID: 21898089 DOI: 10.1007/s00534-011-0440-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
175 Cho EH, Kim JY, Im SA, Jung KH, Sohn J, Lee KS, Chae YS, Lee KH, Kim JH, Jang JH, Ahn JH, Park MS, Lee SY, Park YH. Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11). ESMO Open 2021;6:100236. [PMID: 34438242 DOI: 10.1016/j.esmoop.2021.100236] [Reference Citation Analysis]
176 Sipos B, Sperveslage J. [Will molecular diagnostics become established in pancreatic pathology?]. Pathologe 2013;34 Suppl 2:214-20. [PMID: 24196616 DOI: 10.1007/s00292-013-1865-z] [Reference Citation Analysis]
177 Shin DW, Lee JC, Kim J, Yoon YS, Han HS, Kim H, Hwang JH. Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial. Pancreatology 2021;21:796-804. [PMID: 33795193 DOI: 10.1016/j.pan.2021.02.022] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
178 Giovinazzo F, Turri G, Zanini S, Butturini G, Scarpa A, Bassi C. Clinical implications of biological markers in Pancreatic Ductal Adenocarcinoma. Surg Oncol. 2012;21:e171-e182. [PMID: 22981281 DOI: 10.1016/j.suronc.2012.07.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
179 Damaraju VL, Mowles D, Yao S, Ng A, Young JD, Cass CE, Tong Z. Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine. Nucleosides Nucleotides Nucleic Acids 2012;31:236-55. [PMID: 22356238 DOI: 10.1080/15257770.2011.652330] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
180 Bachet JB, Marechal R, Van Laethem JL. Treatment of pancreatic cancer: what can we really predict today? Cancers (Basel) 2011;3:675-99. [PMID: 24212636 DOI: 10.3390/cancers3010675] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
181 Rizzuto I, Ghazaly E, Peters GJ. Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate. Pharmacogenomics 2017;18:911-25. [PMID: 28594276 DOI: 10.2217/pgs-2017-0034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
182 Pazienza V, Del Nobile Matteo A. Targeting human equilibrative nucleoside analog transporter (hENT1) expression through modified low glycemic index diet in pancreatic cancer. Biomed Pharmacother 2014;68:663-4. [PMID: 24874245 DOI: 10.1016/j.biopha.2014.04.009] [Reference Citation Analysis]
183 Boeck S, Jung A, Laubender RP, Neumann J, Egg R, Goritschan C, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens MR. EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. Br J Cancer. 2013;108:469-476. [PMID: 23169292 DOI: 10.1038/bjc.2012.495] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 6.0] [Reference Citation Analysis]
184 Jiraskova L, Ryska A, Duintjer Tebbens EJ, Hornychova H, Cecka F, Staud F, Cerveny L. Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy? Cancers (Basel) 2019;11:E1621. [PMID: 31652721 DOI: 10.3390/cancers11111621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
185 D'Aronzo M, Vinciguerra M, Mazza T, Panebianco C, Saracino C, Pereira SP, Graziano P, Pazienza V. Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models. Oncotarget 2015;6:18545-57. [PMID: 26176887 DOI: 10.18632/oncotarget.4186] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
186 Richards NG, Rittenhouse DW, Freydin B, Cozzitorto JA, Grenda D, Rui H, Gonye G, Kennedy EP, Yeo CJ, Brody JR, Witkiewicz AK. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. Ann Surg. 2010;252:499-505; discussion 505-6. [PMID: 20739850 DOI: 10.1097/sla.0b013e3181f1fd44] [Cited by in Crossref: 11] [Cited by in F6Publishing: 45] [Article Influence: 0.9] [Reference Citation Analysis]
187 Vijayvergia N, Cohen SJ. Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer? J Gastrointest Oncol 2016;7:727-37. [PMID: 27747087 DOI: 10.21037/jgo.2016.08.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
188 Heinemann V, Haas M, Boeck S. Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev 2012;38:843-53. [PMID: 22226241 DOI: 10.1016/j.ctrv.2011.12.004] [Cited by in Crossref: 81] [Cited by in F6Publishing: 81] [Article Influence: 8.1] [Reference Citation Analysis]
189 Kawada N, Uehara H, Katayama K, Nakamura S, Takahashi H, Ohigashi H, Ishikawa O, Nagata S, Tomita Y. Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine. J Hepatobiliary Pancreat Sci 2012;19:717-22. [PMID: 22426593 DOI: 10.1007/s00534-012-0514-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
190 Conroy T, Ducreux M. Adjuvant treatment of pancreatic cancer. Curr Opin Oncol 2019;31:346-53. [PMID: 30994497 DOI: 10.1097/CCO.0000000000000546] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
191 Frank TS, Sun X, Zhang Y, Yang J, Fisher WE, Gingras MC, Li M. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer. Cancer Lett 2015;363:1-6. [PMID: 25890222 DOI: 10.1016/j.canlet.2015.04.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
192 Crane CH. Is Personalization of Care Coming to Pancreatic Oncology? Ann Surg Oncol 2013;20:355-6. [DOI: 10.1245/s10434-012-2770-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
193 Xu L, Liu YP. Advances in chemotherapy of advanced pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2010; 18(25): 2685-2689 [DOI: 10.11569/wcjd.v18.i25.2685] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
194 Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P, Peeters M, Polus M, Praet M, Mauer M. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol. 2010;28:4450-4456. [PMID: 20837948 DOI: 10.1200/JCO.2010. 30.3446] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
195 Avan A, Maftouh M, Giovannetti E. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: Implication: Correspondence. Cancer 2013;119:2662-3. [DOI: 10.1002/cncr.28116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
196 Fan J, Wei Q, Koay EJ, Liu Y, Ning B, Bernard PW, Zhang N, Han H, Katz MH, Zhao Z, Hu Y. Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer. Theranostics 2018;8:5986-94. [PMID: 30613276 DOI: 10.7150/thno.26650] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 13.8] [Reference Citation Analysis]
197 Di Gangi IM, Vrhovsek U, Pazienza V, Mattivi F. Analytical metabolomics-based approaches to pancreatic cancer. TrAC Trends in Analytical Chemistry 2014;55:94-116. [DOI: 10.1016/j.trac.2013.12.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
198 Jamieson NB, Chang DK, Biankin AV. Cancer Genetics and Implications for Clinical Management. Surgical Clinics of North America 2015;95:919-34. [DOI: 10.1016/j.suc.2015.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
199 Costello E, Greenhalf W, Neoptolemos JP. New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol. 2012;9:435-444. [PMID: 22733351 DOI: 10.1038/nrgastro.2012.119] [Cited by in Crossref: 147] [Cited by in F6Publishing: 140] [Article Influence: 14.7] [Reference Citation Analysis]
200 Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. Methods Mol Biol. 2010;596:47-76. [PMID: 19949920 DOI: 10.1007/978-1-60761-416-6_4] [Cited by in Crossref: 377] [Cited by in F6Publishing: 369] [Article Influence: 31.4] [Reference Citation Analysis]
201 Hidalgo M, Cascinu S, Kleeff J, Labianca R, Löhr JM, Neoptolemos J, Real FX, Van Laethem JL, Heinemann V. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2013;15:8-18. [PMID: 25547205 DOI: 10.1016/j.pan.2014.10.001] [Cited by in Crossref: 222] [Cited by in F6Publishing: 222] [Article Influence: 27.8] [Reference Citation Analysis]
202 Flores JP, Diasio RB, Saif MW. Drug metabolism and pancreatic cancer. Ann Gastroenterol 2017;30:54-61. [PMID: 28042238 DOI: 10.20524/aog.2016.0074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
203 Koikawa K, Kibe S, Suizu F, Sekino N, Kim N, Manz TD, Pinch BJ, Akshinthala D, Verma A, Gaglia G, Nezu Y, Ke S, Qiu C, Ohuchida K, Oda Y, Lee TH, Wegiel B, Clohessy JG, London N, Santagata S, Wulf GM, Hidalgo M, Muthuswamy SK, Nakamura M, Gray NS, Zhou XZ, Lu KP. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell 2021:S0092-8674(21)00879-5. [PMID: 34388391 DOI: 10.1016/j.cell.2021.07.020] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
204 Revalde JL, Li Y, Wijeratne TS, Bugde P, Hawkins BC, Rosengren RJ, Paxton JW. Curcumin and its cyclohexanone analogue inhibited human Equilibrative nucleoside transporter 1 (ENT1) in pancreatic cancer cells. European Journal of Pharmacology 2017;803:167-73. [DOI: 10.1016/j.ejphar.2017.03.055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
205 Yu IS, Cheung WY. A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma. Can J Gastroenterol Hepatol 2018;2018:1863535. [PMID: 29623263 DOI: 10.1155/2018/1863535] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
206 Basu B, Jodrell D. Progress in pancreatic cancer: moving beyond gemcitabine? Expert Rev Anticancer Ther 2012;12:997-1000. [PMID: 23030218 DOI: 10.1586/era.12.78] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
207 Iglesias-Garcia J, Lariño-Noia J, Domínguez-Muñoz JE. When to puncture, when not to puncture: Pancreatic masses. Endosc Ultrasound 2014;3:91-7. [PMID: 24955338 DOI: 10.4103/2303-9027.123007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
208 Ploquin A, Truant S, Piessen G, Vuagnat P, Baldini C, Cattan S, Hebbar M. Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under Gemcitabine. In Vivo 2017;31:731-5. [PMID: 28652448 DOI: 10.21873/invivo.11122] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
209 Okada Y, Nishiwada S, Yamamura K, Sho M, Baba H, Takayama T, Goel A. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma. Eur J Cancer 2021;146:125-34. [PMID: 33607476 DOI: 10.1016/j.ejca.2020.12.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
210 de Sousa Cavalcante L, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014;741:8-16. [PMID: 25084222 DOI: 10.1016/j.ejphar.2014.07.041] [Cited by in Crossref: 258] [Cited by in F6Publishing: 242] [Article Influence: 32.3] [Reference Citation Analysis]
211 Bjerregaard JK, Mortensen MB, Jensen HA, Fristrup C, Svolgaard B, Schønnemann KR, Hansen TP, Nielsen M, Johansen J, Pfeiffer P. Long-term results of concurrent radiotherapy and UFT in patients with locally advanced pancreatic cancer. Radiother Oncol 2009;92:226-30. [PMID: 19435643 DOI: 10.1016/j.radonc.2009.04.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
212 Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res. 2010;16:320-329. [PMID: 20028759 DOI: 10.1158/1078-0432.ccr-09-1555] [Cited by in Crossref: 74] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
213 Borbath I, Verbrugghe L, Lai R, Gigot J, Humblet Y, Piessevaux H, Sempoux C. Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma. European Journal of Cancer 2012;48:990-6. [DOI: 10.1016/j.ejca.2011.11.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 87] [Article Influence: 4.1] [Reference Citation Analysis]
214 Sasaki H, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy. Br J Cancer 2014;111:1275-84. [PMID: 25032731 DOI: 10.1038/bjc.2014.399] [Cited by in Crossref: 19] [Cited by in F6Publishing: 64] [Article Influence: 2.4] [Reference Citation Analysis]
215 Takahashi H, Ohigashi H, Ishikawa O, Gotoh K, Yamada T, Nagata S, Tomita Y, Eguchi H, Doki Y, Yano M. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer. Ann Surg. 2012;255:95-102. [PMID: 22123160 DOI: 10.1097/sla.0b013e31823d813c] [Cited by in Crossref: 79] [Cited by in F6Publishing: 28] [Article Influence: 7.9] [Reference Citation Analysis]
216 Kondo N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Ohge H, Sueda T. Prognostic impact of dihydropyrimidine dehydrogenase expression on pancreatic adenocarcinoma patients treated with S-1-based adjuvant chemotherapy after surgical resection. J Surg Oncol. 2011;104:146-154. [PMID: 21538357 DOI: 10.1002/jso.21955] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
217 Loc WS, Linton SS, Wilczynski ZR, Matters GL, McGovern CO, Abraham T, Fox T, Gigliotti CM, Tang X, Tabakovic A, Martin JA, Clawson GA, Smith JP, Butler PJ, Kester M, Adair JH. Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic cancer. Nanomedicine 2017;13:2313-24. [PMID: 28673852 DOI: 10.1016/j.nano.2017.06.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
218 Bulanadi JC, Xue A, Gong X, Bean PA, Julovi SM, de Campo L, Smith RC, Moghaddam MJ. Biomimetic Gemcitabine-Lipid Prodrug Nanoparticles for Pancreatic Cancer. Chempluschem 2020;85:1283-91. [PMID: 32543086 DOI: 10.1002/cplu.202000253] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
219 Kobayashi H, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T. Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection. Ann Surg 2012;256:288-96. [PMID: 22580938 DOI: 10.1097/SLA.0b013e3182536a42] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
220 Brody JR, Gonye GE. HuR's role in gemcitabine efficacy: an exception or opportunity? Wiley Interdiscip Rev RNA 2011;2:435-44. [PMID: 21957028 DOI: 10.1002/wrna.62] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
221 Sinn M, Riess H, Sinn BV, Stieler JM, Pelzer U, Striefler JK, Oettle H, Bahra M, Denkert C, Bläker H. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial. Eur J Cancer. 2015;51:1546-1554. [PMID: 26049689 DOI: 10.1016/j.ejca.2015.05.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
222 Phua LC, Goh S, Tai DWM, Leow WQ, Alkaff SMF, Chan CY, Kam JH, Lim TKH, Chan ECY. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine. Cancer Chemother Pharmacol 2018;81:277-89. [PMID: 29196965 DOI: 10.1007/s00280-017-3475-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
223 Gayet O, Loncle C, Duconseil P, Gilabert M, Lopez MB, Moutardier V, Turrini O, Calvo E, Ewald J, Giovannini M, Gasmi M, Bories E, Barthet M, Ouaissi M, Goncalves A, Poizat F, Raoul JL, Secq V, Garcia S, Viens P, Dusetti N, Iovanna J. A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. Oncotarget 2015;6:746-54. [PMID: 25481873 DOI: 10.18632/oncotarget.2685] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
224 Sandvold ML, Galmarini C, Myhren F, Peters G. The activity of the lipophilic nucleoside derivatives elacytarabine and CP-4126 in a panel of tumor cell lines resistant to nucleoside analogues. Nucleosides Nucleotides Nucleic Acids 2010;29:386-93. [PMID: 20544524 DOI: 10.1080/15257771003729625] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
225 Chandrasegaram MD, Chen JW, Price TJ, Zalcberg J, Sjoquist K, Merrett ND. Advances in Molecular Pathology and Treatment of Periampullary Cancers. Pancreas. 2016;45:32-39. [PMID: 26348463 DOI: 10.1097/mpa.0000000000000385] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
226 Sawicka E, Mirończuk A, Wojtukiewicz MZ, Sierko E. Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question? Contemp Oncol (Pozn) 2016;20:102-8. [PMID: 27358587 DOI: 10.5114/wo.2016.60066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
227 Xie H, Jiang W, Xiao SY, Liu X. High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma. J Histochem Cytochem. 2013;61:148-155. [PMID: 23124118 DOI: 10.1369/0022155412468137] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
228 Nakagawa N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection. Surgery 2013;153:565-75. [PMID: 23253379 DOI: 10.1016/j.surg.2012.10.010] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
229 Chang DK, Grimmond SM, Biankin AV. Pancreatic cancer genomics. Curr Opin Genet Dev. 2014;24:74-81. [PMID: 24480245 DOI: 10.1016/j.gde.2013.12.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
230 Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, Doi R, Monden M, Hatori T, Tanaka M, Shimada M, Kanemitsu K. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908-915. [PMID: 19690548 DOI: 10.1038/sj.bjc.6605256] [Cited by in Crossref: 293] [Cited by in F6Publishing: 239] [Article Influence: 22.5] [Reference Citation Analysis]
231 Paproski RJ, Yao SY, Favis N, Evans D, Young JD, Cass CE, Zemp RJ. Human concentrative nucleoside transporter 3 transfection with ultrasound and microbubbles in nucleoside transport deficient HEK293 cells greatly increases gemcitabine uptake. PLoS One 2013;8:e56423. [PMID: 23441192 DOI: 10.1371/journal.pone.0056423] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
232 Oettle H. Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside. Cancer Treat Rev. 2014;40:1039-1047. [PMID: 25087471 DOI: 10.1016/j.ctrv.2014.07.003] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 8.6] [Reference Citation Analysis]
233 Maréchal R, Van Laethem J. HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment. Expert Review of Anticancer Therapy 2014;9:1439-41. [DOI: 10.1586/era.09.119] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
234 Skrypek N, Duchêne B, Hebbar M, Leteurtre E, van Seuningen I, Jonckheere N. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Oncogene 2013;32:1714-23. [PMID: 22580602 DOI: 10.1038/onc.2012.179] [Cited by in Crossref: 86] [Cited by in F6Publishing: 85] [Article Influence: 8.6] [Reference Citation Analysis]
235 Bachet JB, Chibaudel B, Bonnetain F, Validire P, Hammel P, André T, Louvet C; GERCOR group. A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial. BMC Cancer 2015;15:653. [PMID: 26445094 DOI: 10.1186/s12885-015-1656-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
236 Prasad B, Vrana M, Mehrotra A, Johnson K, Bhatt DK. The Promises of Quantitative Proteomics in Precision Medicine. J Pharm Sci 2017;106:738-44. [PMID: 27939376 DOI: 10.1016/j.xphs.2016.11.017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
237 Wong PP, Demircioglu F, Ghazaly E, Alrawashdeh W, Stratford MR, Scudamore CL, Cereser B, Crnogorac-Jurcevic T, McDonald S, Elia G, Hagemann T, Kocher HM, Hodivala-Dilke KM. Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. Cancer Cell 2015;27:123-37. [PMID: 25584895 DOI: 10.1016/j.ccell.2014.10.015] [Cited by in Crossref: 124] [Cited by in F6Publishing: 120] [Article Influence: 17.7] [Reference Citation Analysis]
238 Molina-arcas M, Pastor-anglada M. Role of Nucleoside Transporters in Nucleoside-Derived Drug Sensitivity. Nucleosides, Nucleotides and Nucleic Acids 2010;29:335-46. [DOI: 10.1080/15257771003729823] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
239 Saif MW, Lee Y, Kim R. Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. Ther Adv Med Oncol 2012;4:341-6. [PMID: 23118809 DOI: 10.1177/1758834012453755] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
240 Sudo K, Nakamura K, Yamaguchi T. S-1 in the treatment of pancreatic cancer. World J Gastroenterol 2014; 20(41): 15110-15118 [PMID: 25386059 DOI: 10.3748/wjg.v20.i41.15110] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
241 Conroy T, Gavoille C, Adenis A. Metastatic pancreatic cancer: old drugs, new paradigms. Curr Opin Oncol. 2011;23:390-395. [PMID: 21505335 DOI: 10.1097/cco.0b013e3283473610] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
242 Colbert LE, Petrova AV, Fisher SB, Pantazides BG, Madden MZ, Hardy CW, Warren MD, Pan Y, Nagaraju GP, Liu EA. CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. Cancer Res. 2014;74:2677-2687. [PMID: 24626090 DOI: 10.1158/0008-5472.can-13-1996] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
243 Urey C, Andersson B, Ansari D, Sasor A, Said-Hilmersson K, Nilsson J, Andersson R. Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine. Scand J Gastroenterol 2017;52:595-600. [PMID: 28270046 DOI: 10.1080/00365521.2017.1290134] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
244 Parsian M, Unsoy G, Mutlu P, Yalcin S, Tezcaner A, Gunduz U. Loading of Gemcitabine on chitosan magnetic nanoparticles increases the anti-cancer efficacy of the drug. European Journal of Pharmacology 2016;784:121-8. [DOI: 10.1016/j.ejphar.2016.05.016] [Cited by in Crossref: 52] [Cited by in F6Publishing: 36] [Article Influence: 8.7] [Reference Citation Analysis]
245 Lamba JK. Genetic factors influencing cytarabine therapy. Pharmacogenomics 2009;10:1657-74. [PMID: 19842938 DOI: 10.2217/pgs.09.118] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 6.5] [Reference Citation Analysis]
246 Ruiz C, Lenkiewicz E, Evers L, Holley T, Robeson A, Kiefer J, Demeure MJ, Hollingsworth MA, Shen M, Prunkard D, Rabinovitch PS, Zellweger T, Mousses S, Trent JM, Carpten JD, Bubendorf L, Von Hoff D, Barrett MT. Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci U S A 2011;108:12054-9. [PMID: 21730190 DOI: 10.1073/pnas.1104009108] [Cited by in Crossref: 83] [Cited by in F6Publishing: 77] [Article Influence: 7.5] [Reference Citation Analysis]
247 Lemstrová R, Souček P, Melichar B, Mohelnikova-duchonova B. Role of solute carrier transporters in pancreatic cancer: a review. Pharmacogenomics 2014;15:1133-45. [DOI: 10.2217/pgs.14.80] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
248 Maréchal R, Demols A, Van Laethem JL. Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer. Drugs Aging 2013;30:155-65. [PMID: 23338795 DOI: 10.1007/s40266-013-0049-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
249 Greene MK, Johnston MC, Scott CJ. Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance. Cancers (Basel) 2021;13:6175. [PMID: 34944794 DOI: 10.3390/cancers13246175] [Reference Citation Analysis]
250 Ansari D, Rosendahl A, Elebro J, Andersson R. Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br J Surg. 2011;98:1041-1055. [PMID: 21644238 DOI: 10.1002/bjs.7574] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 6.7] [Reference Citation Analysis]
251 Sutton JM, Abbott DE. Neoadjuvant therapy for pancreas cancer: Past lessons and future therapies. World J Gastroenterol 2014; 20(42): 15564-15579 [PMID: 25400440 DOI: 10.3748/wjg.v20.i42.15564] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
252 Bachet JB, Maréchal R, Demetter P, Bonnetain F, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Ann Oncol. 2012;23:2327-2335. [PMID: 22377565 DOI: 10.1093/annonc/mdr617] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 5.6] [Reference Citation Analysis]
253 Caparello C, Meijer LL, Garajova I, Falcone A, Le Large TY, Funel N, Kazemier G, Peters GJ, Vasile E, Giovannetti E. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World J Gastroenterol 2016; 22(31): 6987-7005 [PMID: 27610011 DOI: 10.3748/wjg.v22.i31.6987] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
254 Lawrence B, Findlay M. Systemic therapy for metastatic pancreatic adenocarcinoma. Ther Adv Med Oncol 2010;2:85-106. [PMID: 21789129 DOI: 10.1177/1758834009357188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
255 Sukharamwala P, Hennessey D, Wood T, Singh S, Ryan C, Rosemurgy A. Molecular profiles in foregut oncology. Cancer Genet 2016;209:537-53. [PMID: 27887938 DOI: 10.1016/j.cancergen.2016.09.008] [Reference Citation Analysis]
256 Köse M, Schiedel AC. Nucleoside/nucleobase transporters: drug targets of the future? Future Med Chem 2009;1:303-26. [PMID: 21425971 DOI: 10.4155/fmc.09.29] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
257 Varadhachary GR. Preoperative therapies for resectable and borderline resectable pancreatic cancer. J Gastrointest Oncol. 2011;2:136-142. [PMID: 22811843 DOI: 10.3978/j.issn.2078-6891.2011.030] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
258 Spratlin JL, Mulder KE. Looking to the future: biomarkers in the management of pancreatic adenocarcinoma. Int J Mol Sci 2011;12:5895-907. [PMID: 22016635 DOI: 10.3390/ijms12095895] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
259 Soo RA, Yong WP, Innocenti F. Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets. 2012;13:811-828. [PMID: 22458528 DOI: 10.1016/j.pestbp.2011.02.012.investigations] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
260 Lowery MA, O'Reilly EM. Genomics and pharmacogenomics of pancreatic adenocarcinoma. Pharmacogenomics J 2012;12:1-9. [PMID: 22186617 DOI: 10.1038/tpj.2011.52] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
261 Kanamala M, Palmer BD, Ghandehari H, Wilson WR, Wu Z. PEG-Benzaldehyde-Hydrazone-Lipid Based PEG-Sheddable pH-Sensitive Liposomes: Abilities for Endosomal Escape and Long Circulation. Pharm Res 2018;35:154. [PMID: 29855807 DOI: 10.1007/s11095-018-2429-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
262 Kell DB. Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it. FEBS J. 2013;280:5957-5980. [PMID: 23552054 DOI: 10.1111/febs.12268] [Cited by in Crossref: 81] [Cited by in F6Publishing: 67] [Article Influence: 9.0] [Reference Citation Analysis]
263 Tong Z, Yerramilli U, Yao S, Young JD, Hoffmann M, Surapaneni S. In vitro inhibition of human nucleoside transporters and uptake of azacitidine by an isocitrate dehydrogenase-2 inhibitor enasidenib and its metabolite AGI-16903. Xenobiotica 2019;49:1229-36. [DOI: 10.1080/00498254.2018.1539783] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
264 Chen Z, Zheng Y, Shi Y, Cui Z. Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles. Int J Nanomedicine 2018;13:319-36. [PMID: 29391792 DOI: 10.2147/IJN.S149196] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
265 Sturm N, Ettrich TJ, Perkhofer L. The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy. Cancers (Basel) 2022;14:217. [PMID: 35008381 DOI: 10.3390/cancers14010217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Liu ZQ, Han YC, Zhang X, Chu L, Fang JM, Zhao HX, Chen YJ, Xu Q. Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis. PLoS One. 2014;9:e87103. [PMID: 24475233 DOI: 10.1371/journal.pone.0087103] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
267 Cuthbertson CR, Guo H, Kyani A, Madak JT, Arabzada Z, Neamati N. The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors. ACS Pharmacol Transl Sci 2020;3:1242-52. [PMID: 33344900 DOI: 10.1021/acsptsci.0c00124] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
268 Farrell JJ, Moughan J, Wong JL, Regine WF, Schaefer P, Benson AB 3rd, Macdonald JS, Liu X, Yen Y, Lai R, Zheng Z, Bepler G, Guha C, Elsaleh H. Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach. Pancreas 2016;45:1485-93. [PMID: 27748721 DOI: 10.1097/MPA.0000000000000710] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
269 Murata A, Amano R, Yamada N, Kimura K, Yashiro M, Nakata B, Hirakawa K. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone. World J Surg Oncol. 2013;11:117. [PMID: 23710668 DOI: 10.1186/1477-7819-11-117] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
270 Liang C, Shi S, Meng Q, Liang D, Ji S, Zhang B, Qin Y, Xu J, Ni Q, Yu X. Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer? Cell Mol Life Sci 2018;75:1001-12. [DOI: 10.1007/s00018-017-2678-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
271 Tanaka M, Javle M, Dong X, Eng C, Abbruzzese JL, Li D. Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer 2010;116:5325-35. [PMID: 20665488 DOI: 10.1002/cncr.25282] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 5.3] [Reference Citation Analysis]
272 Taieb J, Pointet AL, Van Laethem JL, Laquente B, Pernot S, Lordick F, Reni M. What treatment in 2017 for inoperable pancreatic cancers? Ann Oncol. 2017;28:1473-1483. [PMID: 28459988 DOI: 10.1093/annonc/mdx174] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
273 Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia. 2010;12:807-817. [PMID: 20927319 DOI: 10.1593/neo. 10458] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
274 Kazemi-andalib F, Mohammadikish M, Divsalar A, Sahebi U. Hollow microcapsule with pH-sensitive chitosan/polymer shell for in vitro delivery of curcumin and gemcitabine. European Polymer Journal 2022;162:110887. [DOI: 10.1016/j.eurpolymj.2021.110887] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
275 Boswell-Casteel RC, Johnson JM, Hays FA. Functional Characterization of the Saccharomyces cerevisiae Equilibrative Nucleoside Transporter 1 (ScENT1). Molecules 2018;23:E732. [PMID: 29565807 DOI: 10.3390/molecules23040732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
276 Jiang XX, Fu HQ, Chao YH, Liu ZY. Expression characteristics of ENT1 in human hepatocellular carcinoma cells. Shijie Huaren Xiaohua Zazhi 2011; 19(20): 2104-2108 [DOI: 10.11569/wcjd.v19.i20.2104] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
277 Maréchal R, Puleo F, Demols A, Verset G, Laethem JV. Personalized medicine in pancreatic cancer: the revolution has begun. Per Med 2015;12:515-23. [PMID: 29749894 DOI: 10.2217/pme.15.15] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
278 Liang AL, Du SL, Zhang B, Zhang J, Ma X, Wu CY, Liu YJ. Screening miRNAs associated with resistance gemcitabine from exosomes in A549 lung cancer cells. Cancer Manag Res 2019;11:6311-21. [PMID: 31372037 DOI: 10.2147/CMAR.S209149] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
279 Mohelnikova-Duchonova B, Melichar B. Human equilibrative nucleoside transporter 1 (hENT1): do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients? Pancreatology. 2013;13:558-563. [PMID: 24280569 DOI: 10.1016/j.pan.2013.09.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
280 Viterbo D, Gausman V, Gonda T. Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy. World J Gastrointest Endosc 2016; 8(3): 128-142 [PMID: 26862363 DOI: 10.4253/wjge.v8.i3.128] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
281 Dai J, Zhang Y, Li H, Deng Y, Elzatahry AA, Alghamdi A, Fu D, Jiang Y, Zhao D. Enhancement of gemcitabine against pancreatic cancer by loading in mesoporous silica vesicles. Chinese Chemical Letters 2017;28:531-6. [DOI: 10.1016/j.cclet.2016.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
282 Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia. 2010;12:807-817. [PMID: 20927319 DOI: 10.1593/neo. 10458] [Reference Citation Analysis]
283 Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Salmon I, Devière J, Van Laethem J. Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer 2010;116:5200-6. [DOI: 10.1002/cncr.25303] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 4.0] [Reference Citation Analysis]
284 Vege SS, Pandol SJ. Advances in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasms, and Pancreatitis. Gastroenterology 2018;155:581-3. [PMID: 29753841 DOI: 10.1053/j.gastro.2018.05.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
285 Park S, Kim JW, Kim H, Kim JW, Kim YJ, Lee KW, Kim JH, Kim JH, Hwang JH, Choi YR. Prognostic value of p21-activated kinase 4 in resected pancreatic cancer. APMIS. 2017;125:699-707. [PMID: 28556956 DOI: 10.1111/apm.12705] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
286 Yoneyama H, Takizawa-hashimoto A, Takeuchi O, Watanabe Y, Atsuda K, Asanuma F, Yamada Y, Suzuki Y. Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones. Anti-Cancer Drugs 2015;26:90-100. [DOI: 10.1097/cad.0000000000000165] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
287 Huguet F, Fernet M, Monnier L, Touboul E, Favaudon V. [New perspectives for radiosensitization in pancreatic carcinoma: a review of mechanisms involved in pancreatic tumorigenesis]. Cancer Radiother 2011;15:365-75. [PMID: 21664851 DOI: 10.1016/j.canrad.2011.04.001] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
288 Bhutia YD, Hung SW, Patel B, Lovin D, Govindarajan R. CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res 2011;71:1825-35. [PMID: 21343396 DOI: 10.1158/0008-5472.CAN-10-2736] [Cited by in Crossref: 64] [Cited by in F6Publishing: 38] [Article Influence: 5.8] [Reference Citation Analysis]
289 Tu M, Li H, Lv N, Xi C, Lu Z, Wei J, Chen J, Guo F, Jiang K, Song G, Gao W, Miao Y. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2. Mol Cancer 2017;16:66. [PMID: 28327155 DOI: 10.1186/s12943-017-0619-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
290 Brody JR, Witkiewicz AK, Yeo CJ. The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer. Adv Surg. 2011;45:301-321. [PMID: 21954696 DOI: 10.1016/j.yasu.2011.04.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
291 Levy MJ, Alberts SR, Bamlet WR, Burch PA, Farnell MB, Gleeson FC, Haddock MG, Kendrick ML, Oberg AL, Petersen GM, Takahashi N, Chari ST. EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer. Gastrointest Endosc 2017;86:161-9. [PMID: 27889543 DOI: 10.1016/j.gie.2016.11.014] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
292 Paulson AS, Tran Cao HS, Tempero MA, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology. 2013;144:1316-1326. [PMID: 23622141 DOI: 10.1053/j.gastro.2013.01.078] [Cited by in Crossref: 188] [Cited by in F6Publishing: 181] [Article Influence: 20.9] [Reference Citation Analysis]
293 Jamorabo DS, Lin SH, Jabbour SK. Successes and Failures of Combined Modalities in Upper Gastrointestinal Malignancies: New Directions. Seminars in Radiation Oncology 2016;26:307-19. [DOI: 10.1016/j.semradonc.2016.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
294 Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6:321-337. [PMID: 23814611 DOI: 10.1177/1756283x13478680] [Cited by in Crossref: 155] [Cited by in F6Publishing: 104] [Article Influence: 17.2] [Reference Citation Analysis]
295 Svrcek M, Cros J, Maréchal R, Bachet JB, Fléjou JF, Demetter P. Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies. Histopathology 2015;66:457-62. [PMID: 25298108 DOI: 10.1111/his.12577] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
296 Voutsadakis IA. Molecular predictors of gemcitabine response in pancreatic cancer. World J Gastrointest Oncol 2011; 3(11): 153-164 [PMID: 22110842 DOI: 10.4251/wjgo.v3.i11.153] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
297 Buanes TA. Pancreatic cancer-improved care achievable. World J Gastroenterol 2014; 20(30): 10405-10418 [PMID: 25132756 DOI: 10.3748/wjg.v20.i30.10405] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
298 Buc E, Couvelard A, Kwiatkowski F, Dokmak S, Ruszniewski P, Hammel P, Belghiti J, Sauvanet A. Adenocarcinoma of the pancreas: Does prognosis depend on mode of lymph node invasion? European Journal of Surgical Oncology (EJSO) 2014;40:1578-85. [DOI: 10.1016/j.ejso.2014.04.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
299 Pastor-Anglada M, Pérez-Torras S. Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. Front Pharmacol 2015;6:13. [PMID: 25713533 DOI: 10.3389/fphar.2015.00013] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 8.7] [Reference Citation Analysis]
300 Yee NS. Toward the goal of personalized therapy in pancreatic cancer by targeting the molecular phenotype. Adv Exp Med Biol 2013;779:91-143. [PMID: 23288637 DOI: 10.1007/978-1-4614-6176-0_5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
301 Hagmann W, Jesnowski R, Löhr JM. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia 2010;12:740-7. [PMID: 20824050 DOI: 10.1593/neo.10576] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 6.8] [Reference Citation Analysis]
302 Ko AH. Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities. J Clin Oncol. 2015;33:1779-1786. [PMID: 25918299 DOI: 10.1200/jco.2014.59.7625] [Cited by in Crossref: 49] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
303 Cazacu IM, Luzuriaga Chavez AA, Saftoiu A, Vilmann P, Bhutani MS. A quarter century of EUS-FNA: Progress, milestones, and future directions. Endosc Ultrasound. 2018;7:141-160. [PMID: 29941723 DOI: 10.4103/eus.eus_19_18] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 8.3] [Reference Citation Analysis]